Search results
Results from the WOW.Com Content Network
Adverse effects that threaten serious harm, aggravate other medical conditions, or make a person want to stop taking their medications are all examples of drug intolerance. Certain drug interactions can cause adverse effects as well. [1] Patient/guardian preference: A patient or caregiver may prefer a different antipsychotic. This may be due to ...
Olanzapine, sold under the brand name Zyprexa among others, is an atypical antipsychotic primarily used to treat schizophrenia and bipolar disorder. [13] It is also sometimes used off-label for treatment of chemotherapy-induced nausea and vomiting [14] and as an appetite stimulant. [15]
One of the safer techniques simply reduces your current dosage to a complete stop, then waits for it to clear your body before starting the new antidepressant. You may need to use this technique ...
Generally, tapering is done is to avoid or minimize withdrawal symptoms that arise from neurobiological adaptation to the drug. [1] [2] Prescribed psychotropic drugs that may require tapering due to this physical dependence include opioids, [3] [4] [5] selective serotonin reuptake inhibitors, [6] antipsychotics, [7] anticonvulsants, [8] and ...
Patients who wish to come off the drugs permanently should first agree with their doctor whether it is right to stop taking the medication, and, if so, the speed and duration of withdrawal from it ...
Online, people claim they get brain zaps after stopping use of drugs like Lexapro (escitalopram), Cymbalta (duloxetine), and Paxil (paroxetine), but they can happen when you stop taking any type ...
Olanzapine/fluoxetine (trade name Symbyax, created by Eli Lilly and Company) is a fixed-dose combination medication containing olanzapine (Zyprexa), an atypical antipsychotic, and fluoxetine (Prozac), a selective serotonin reuptake inhibitor (SSRI).
These side effects are serious and some of them are permanent, and many remain a crucial concern for companies and healthcare professionals and substantial efforts are being encouraged to reduce the potential risks for future antipsychotics through more clinical trials and drug development.